Zentalis Pharmaceuticals Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
ZNTL$1.80+3.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2024 | 2023 | |
| License Revenue | $40,560 | $— |
| Operating Expenses | ||
| Research and development | 49,585 | 48,584 |
| General and administrative | 15,740 | 16,369 |
| Total operating expenses | 65,325 | 64,953 |
| Loss from operations | (24,765) | (64,953) |
| Other Income (Expense) | ||
| Investment and other income, net | 34,948 | 4,109 |
| Net income (loss) before income taxes | 10,183 | (60,844) |
| Income tax expense | 143 | 108 |
| Loss on equity method investment | — | 2,310 |
| Net income (loss) | 10,040 | (63,262) |
| Net loss attributable to noncontrolling interests | (28) | (43) |
| Net income (loss) attributable to Zentalis | $10,068 | $(63,219) |
| Earnings per share | ||
| Basic | $0.14 | $(1.07) |
| Diluted | $0.14 | $(1.07) |
| Weighted average common shares outstanding | ||
| Basic | 70,898 | 59,277 |
| Diluted | 71,192 | 59,277 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.